MediciNova,Inc. Logo

MediciNova,Inc.

Developing small-molecule drugs for neurology, respiratory, and liver diseases.

4875 | T

Overview

Corporate Details

ISIN(s):
US58468P2065
LEI:
Country:
Japan
Address:
米国カリフォルニア州ラ・ホイヤ、スウィート300、エグゼクティブ・スクエア4275
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for serious diseases with unmet medical needs. The company's primary development efforts are concentrated on neurology, respiratory, and liver diseases. Its pipeline includes candidates such as MN-221, targeting respiratory conditions like acute exacerbations of asthma and COPD, and MN-001 for fibrotic diseases, including liver fibrosis (NASH) and idiopathic pulmonary fibrosis (IPF).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 07:44
Registration Form
確認書
Japanese 8.4 KB
2025-09-12 07:43
Interim Report
半期報告書
Japanese 386.0 KB
2025-06-25 03:32
Regulatory News Service
臨時報告書
Japanese 16.6 KB
2025-06-10 06:52
Audit Report / Information
内部統制報告書
Japanese 51.3 KB
2025-06-10 06:51
Registration Form
確認書
Japanese 12.9 KB
2025-06-10 06:50
Annual Report
有価証券報告書
Japanese 3.0 MB
2024-09-11 04:32
Registration Form
確認書
Japanese 13.0 KB
2024-09-11 04:28
Interim Report
半期報告書
Japanese 436.9 KB
2024-06-17 09:06
Post-Annual General Meeting Information
臨時報告書
Japanese 15.4 KB
2024-06-13 05:03
Registration Form
確認書
Japanese 13.1 KB
2024-06-13 05:02
Quarterly Report
四半期報告書
Japanese 424.9 KB
2024-06-10 09:48
Audit Report / Information
内部統制報告書
Japanese 51.4 KB
2024-06-10 09:46
Audit Report / Information
有価証券報告書
Japanese 3.3 MB
2024-06-10 09:46
Registration Form
確認書
Japanese 12.9 KB
2023-12-12 06:01
Registration Form
確認書
Japanese 13.1 KB

Automate Your Workflow. Get a real-time feed of all MediciNova,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MediciNova,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MediciNova,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden
KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America
KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea
038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea
256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan
4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland
KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA
KIORA PHARMACEUTICALS INC Logo
Developing advanced small molecule therapies for vision-threatening retinal diseases.
United States of America
KPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.